1 November 2024 false No description of principal activity Taxfiler 2024.6 12983269business:PrivateLimitedCompanyLtd2024-11-012025-10-31 129832692024-10-31 129832692024-11-012025-10-31 12983269business:AuditExemptWithAccountantsReport2024-11-012025-10-31 12983269business:FilletedAccounts2024-11-012025-10-31 129832692025-10-31 12983269business:Director12024-11-012025-10-31 12983269business:Director22024-11-012025-10-31 12983269business:RegisteredOffice2024-11-012025-10-31 129832692024-10-31 12983269core:WithinOneYear2025-10-31 12983269core:WithinOneYear2024-10-31 12983269core:AfterOneYear2025-10-31 12983269core:AfterOneYear2024-10-31 12983269core:ShareCapitalcore:PreviouslyStatedAmount2025-10-31 12983269core:ShareCapitalcore:PreviouslyStatedAmount2024-10-31 12983269core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-10-31 12983269core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-10-31 12983269core:PreviouslyStatedAmount2025-10-31 12983269core:PreviouslyStatedAmount2024-10-31 12983269business:SmallEntities2024-11-012025-10-31 12983269countries:EnglandWales2024-11-012025-10-31 12983269core:IntangibleAssetsOtherThanGoodwill2024-10-31 12983269core:IntangibleAssetsOtherThanGoodwill2025-10-31 12983269core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-31 12983269core:PlantMachinery2024-10-31 12983269core:PlantMachinery2025-10-31 12983269core:PlantMachinery2024-11-012025-10-31 129832692023-11-012024-10-31 iso4217:GBP xbrli:pure
Company Registration No. 12983269 (England and Wales)
Northfield Pharmaceuticals Ltd Unaudited accounts for the year ended 31 October 2025
Northfield Pharmaceuticals Ltd Unaudited accounts Contents
Page
- 2 -
Northfield Pharmaceuticals Ltd Company Information for the year ended 31 October 2025
Directors
Mr M A Daji Mr M I Akudi
Company Number
12983269 (England and Wales)
Registered Office
10 Northfield Road Dewsbury West Yorkshire WF13 2JX England
- 3 -
Northfield Pharmaceuticals Ltd Statement of financial position as at 31 October 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Intangible assets
213,307 
243,779 
Tangible assets
1,040 
1,387 
214,347 
245,166 
Current assets
Inventories
32,638 
32,458 
Debtors
108,731 
95,025 
Cash at bank and in hand
133,266 
77,360 
274,635 
204,843 
Creditors: amounts falling due within one year
(113,869)
(105,071)
Net current assets
160,766 
99,772 
Total assets less current liabilities
375,113 
344,938 
Creditors: amounts falling due after more than one year
(266,971)
(288,271)
Net assets
108,142 
56,667 
Capital and reserves
Called up share capital
2 
2 
Profit and loss account
108,140 
56,665 
Shareholders' funds
108,142 
56,667 
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 11 September 2026 and were signed on its behalf by
Mr M A Daji Director Company Registration No. 12983269
- 4 -
Northfield Pharmaceuticals Ltd Notes to the Accounts for the year ended 31 October 2025
1
Statutory information
Northfield Pharmaceuticals Ltd is a private company, limited by shares, registered in England and Wales, registration number 12983269. The registered office is 10 Northfield Road, Dewsbury, West Yorkshire, WF13 2JX, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Other 
£ 
Cost
At 1 November 2024
304,723 
At 31 October 2025
304,723 
Amortisation
At 1 November 2024
60,944 
Charge for the year
30,472 
At 31 October 2025
91,416 
Net book value
At 31 October 2025
213,307 
At 31 October 2024
243,779 
- 5 -
Northfield Pharmaceuticals Ltd Notes to the Accounts for the year ended 31 October 2025
5
Tangible fixed assets
Plant & machinery 
£ 
Cost or valuation
At cost 
At 1 November 2024
1,850 
At 31 October 2025
1,850 
Depreciation
At 1 November 2024
463 
Charge for the year
347 
At 31 October 2025
810 
Net book value
At 31 October 2025
1,040 
At 31 October 2024
1,387 
6
Debtors
2025 
2024 
£ 
£ 
Amounts falling due after more than one year
Trade debtors
92,994 
82,794 
Other debtors
15,737 
12,231 
108,731 
95,025 
7
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Trade creditors
101,166 
86,371 
Taxes and social security
12,511 
18,654 
Other creditors
192 
46 
113,869 
105,071 
8
Creditors: amounts falling due after more than one year
2025 
2024 
£ 
£ 
Other creditors
266,971 
288,271 
9
Average number of employees
During the year the average number of employees was 0 (2024: 0).
- 6 -